Research programme: diabetes cell therapies - Sernova

Drug Profile

Research programme: diabetes cell therapies - Sernova

Alternative Names: Cell Pouch™ - diabetes cell therapy; Sertolin™ - diabetes cell therapy

Latest Information Update: 03 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JDRF; Sertoli Technologies
  • Developer Sernova Corp
  • Class Cell therapies
  • Mechanism of Action Immunomodulators; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in Canada (SC, Implant)
  • 10 Sep 2015 Sernova in-licenses proprietary stem cell derived technologies from the University Health Network (UHN) of Toronto for insulin-dependent diabetes
  • 23 Apr 2015 Sernova receives patent allowance for Cell Pouch™ technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top